Therapeutic drug monitoring of vancomycin in a morbidly obese patient

Scott Robert Penzak, Paul O. Gubbins, Keith A. Rodvold, Steve L. Hickerson

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The authors describe the therapeutic drug monitoring of vancomycin in a man who is morbidly obese. Because serum vancomycin concentration (SVC) monitoring continues to be deemphasized, nomogram use will likely increase. However, vancomycin dosing nomograms have not been studied in patients who are morbidly obese. Furthermore, in nomograms that incorporate body weight, it is unclear whether ideal or total body weight (IBW and TBW, respectively) should be used to dose the morbidly obese. Therefore, the authors retrospectively evaluated four nomograms (Moellering, Matzke, Lake-Peterson, and Rodvold) and an individualized method in the simulated vancomycin dosing of their patient. Total body weight was more accurate than IBW in selecting a vancomycin dose when using the individualized method and in all nomograms except the Matzke nomogram. The Rodvold nomogram and the individualized method yielded the most appropriate doses. All nomograms suggested dosing intervals that were unacceptably short; the individualized method suggested an appropriately longer interval. Thus, if nomograms or the individualized method are used to empirically dose vancomycin, TBW - not IBW - should be used. Because these nomograms yielded inappropriately short dosing intervals in the patient, it is likely that patients who are morbidly obese represent a unique population in which at least one set of SVCs are necessary to select an appropriate dosing regimen.

Original languageEnglish
Pages (from-to)261-265
Number of pages5
JournalTherapeutic Drug Monitoring
Volume20
Issue number3
DOIs
StatePublished - 1 Jan 1998

Fingerprint

Nomograms
Drug Monitoring
Vancomycin
Monitoring
Pharmaceutical Preparations
Body Weight
Lakes

Keywords

  • Obesity
  • Therapeutic drug monitoring
  • Vancomycin

Cite this

Penzak, Scott Robert ; Gubbins, Paul O. ; Rodvold, Keith A. ; Hickerson, Steve L. / Therapeutic drug monitoring of vancomycin in a morbidly obese patient. In: Therapeutic Drug Monitoring. 1998 ; Vol. 20, No. 3. pp. 261-265.
@article{6e9f4528212d418092897d3b0552887a,
title = "Therapeutic drug monitoring of vancomycin in a morbidly obese patient",
abstract = "The authors describe the therapeutic drug monitoring of vancomycin in a man who is morbidly obese. Because serum vancomycin concentration (SVC) monitoring continues to be deemphasized, nomogram use will likely increase. However, vancomycin dosing nomograms have not been studied in patients who are morbidly obese. Furthermore, in nomograms that incorporate body weight, it is unclear whether ideal or total body weight (IBW and TBW, respectively) should be used to dose the morbidly obese. Therefore, the authors retrospectively evaluated four nomograms (Moellering, Matzke, Lake-Peterson, and Rodvold) and an individualized method in the simulated vancomycin dosing of their patient. Total body weight was more accurate than IBW in selecting a vancomycin dose when using the individualized method and in all nomograms except the Matzke nomogram. The Rodvold nomogram and the individualized method yielded the most appropriate doses. All nomograms suggested dosing intervals that were unacceptably short; the individualized method suggested an appropriately longer interval. Thus, if nomograms or the individualized method are used to empirically dose vancomycin, TBW - not IBW - should be used. Because these nomograms yielded inappropriately short dosing intervals in the patient, it is likely that patients who are morbidly obese represent a unique population in which at least one set of SVCs are necessary to select an appropriate dosing regimen.",
keywords = "Obesity, Therapeutic drug monitoring, Vancomycin",
author = "Penzak, {Scott Robert} and Gubbins, {Paul O.} and Rodvold, {Keith A.} and Hickerson, {Steve L.}",
year = "1998",
month = "1",
day = "1",
doi = "10.1097/00007691-199806000-00005",
language = "English",
volume = "20",
pages = "261--265",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "3",

}

Therapeutic drug monitoring of vancomycin in a morbidly obese patient. / Penzak, Scott Robert; Gubbins, Paul O.; Rodvold, Keith A.; Hickerson, Steve L.

In: Therapeutic Drug Monitoring, Vol. 20, No. 3, 01.01.1998, p. 261-265.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Therapeutic drug monitoring of vancomycin in a morbidly obese patient

AU - Penzak, Scott Robert

AU - Gubbins, Paul O.

AU - Rodvold, Keith A.

AU - Hickerson, Steve L.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - The authors describe the therapeutic drug monitoring of vancomycin in a man who is morbidly obese. Because serum vancomycin concentration (SVC) monitoring continues to be deemphasized, nomogram use will likely increase. However, vancomycin dosing nomograms have not been studied in patients who are morbidly obese. Furthermore, in nomograms that incorporate body weight, it is unclear whether ideal or total body weight (IBW and TBW, respectively) should be used to dose the morbidly obese. Therefore, the authors retrospectively evaluated four nomograms (Moellering, Matzke, Lake-Peterson, and Rodvold) and an individualized method in the simulated vancomycin dosing of their patient. Total body weight was more accurate than IBW in selecting a vancomycin dose when using the individualized method and in all nomograms except the Matzke nomogram. The Rodvold nomogram and the individualized method yielded the most appropriate doses. All nomograms suggested dosing intervals that were unacceptably short; the individualized method suggested an appropriately longer interval. Thus, if nomograms or the individualized method are used to empirically dose vancomycin, TBW - not IBW - should be used. Because these nomograms yielded inappropriately short dosing intervals in the patient, it is likely that patients who are morbidly obese represent a unique population in which at least one set of SVCs are necessary to select an appropriate dosing regimen.

AB - The authors describe the therapeutic drug monitoring of vancomycin in a man who is morbidly obese. Because serum vancomycin concentration (SVC) monitoring continues to be deemphasized, nomogram use will likely increase. However, vancomycin dosing nomograms have not been studied in patients who are morbidly obese. Furthermore, in nomograms that incorporate body weight, it is unclear whether ideal or total body weight (IBW and TBW, respectively) should be used to dose the morbidly obese. Therefore, the authors retrospectively evaluated four nomograms (Moellering, Matzke, Lake-Peterson, and Rodvold) and an individualized method in the simulated vancomycin dosing of their patient. Total body weight was more accurate than IBW in selecting a vancomycin dose when using the individualized method and in all nomograms except the Matzke nomogram. The Rodvold nomogram and the individualized method yielded the most appropriate doses. All nomograms suggested dosing intervals that were unacceptably short; the individualized method suggested an appropriately longer interval. Thus, if nomograms or the individualized method are used to empirically dose vancomycin, TBW - not IBW - should be used. Because these nomograms yielded inappropriately short dosing intervals in the patient, it is likely that patients who are morbidly obese represent a unique population in which at least one set of SVCs are necessary to select an appropriate dosing regimen.

KW - Obesity

KW - Therapeutic drug monitoring

KW - Vancomycin

UR - http://www.scopus.com/inward/record.url?scp=0031864171&partnerID=8YFLogxK

U2 - 10.1097/00007691-199806000-00005

DO - 10.1097/00007691-199806000-00005

M3 - Article

C2 - 9631922

AN - SCOPUS:0031864171

VL - 20

SP - 261

EP - 265

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 3

ER -